Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8382199 | 0.98 | NOS2 (0.96) | NOS2TSHRNOS3HTR5ABCHE | |
| Ethane SCHEMBL27508158 | 0.93 | NOS2 (0.86) | NOS2TSHRNOS3HTR5ABCHE | |
| SCHEMBL15650452 | 0.75 | NOS2 (0.60) | NOS2BCHEACHEBRD4 | |
| SCHEMBL13585229 | 0.72 | NOS2 (0.56) | NOS2 | |
| SCHEMBL2658675 | 0.72 | NOS2 (0.56) | NOS2TSHRHTR5A | |
| SCHEMBL12718599 | 0.71 | NOS2 (0.55) | NOS2NOS3HTR5A | |
| SCHEMBL27416904 | 0.71 | NOS2 (0.55) | NOS2 | |
| Methylamine SCHEMBL27663588 | 0.70 | NOS2 (0.53) | NOS2 | |
| SCHEMBL5220692 | 0.69 | NOS2 (0.53) | NOS2TSHR | |
| SCHEMBL17735378 | 0.69 | NOS2 (0.53) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248745-B1 | MIXTURE COMPRISING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR AND A 1,2-DIHYDRO-4-AMINOQUINAZOLINE DERIVATIVE INHIBITOR OF INDUCED NITRIC OXIDE SYNTHASE (INOS); NON-STEROIDAL ANTIINFLAMMATORY AGENTS | ASTRAZENECA AB (SE) | 2001-06-19 | — | — | US | claimed |
| US-9603848-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2015068773-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 石原産業株式会社 | 2015-05-14 | — | — | WO | disclosed |
| EP-2265613-B1 | QUINAZOLINE LINKED PYRROLO[2,1-C][1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2013-07-24 | — | — | EP | disclosed |
| US-7928111-B2 | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors | SENOMYX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306093-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| CN-1204327-A | Pharmaceutically active quinazoline compounds | ASTRA PHARMA PROD (GB) | 1999-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306093-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | NOS2 4603/4885TSHR 423/4885NOS3 4123/4885 |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | NOS2 4603/4885TSHR 423/4885NOS3 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.